NABRIVA THERAPEUTICS AG (NASDAQ:NBRV) Files An 8-K Regulation FD Disclosure

ME Staff 8-k
-
0

NABRIVA THERAPEUTICS AG (NASDAQ:NBRV) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

On March 27, 2017, Nabriva Therapeutics AG (the “Company”) issued a press release announcing its participation at the Needham and Company investor conference on April 5, 2017. Information about accessing a live webcast and a subsequent replay of the Company’s presentation at the conference is included in the press release, which is attached hereto as Exhibit 99.1 and is incorporated by reference into this Form 8-K.

The Company also intends to meet with additional investors and analysts over the course of the next several weeks. A copy of the materials to be used at these meetings, which will also be referenced at the Company’s presentation at its investor conference, is attached hereto as Exhibit 99.2 and is incorporated by reference into this Form 8-K.

The information in this Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

See Exhibit Index attached hereto.


About NABRIVA THERAPEUTICS AG (NASDAQ:NBRV)

Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its product pipeline includes lefamulin, a Phase Three plueromutilin antibiotic in intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), and BC-7013, a Phase One topical pleuromutilin treatment for Gram-positive infections, including uncomplicated skin and skin structure infections (uSSSSIs). In addition, the Company has completed a Phase Two clinical trial for acute bacterial skin and skin structure infections (ABSSSI) and Discovery Phase development of extended-spectrum pleuromutilins (ESPs), a pleuromutilin compound that treats Gram-negative bacteria. The Company is a spin-off of Sandoz GmbH.

NABRIVA THERAPEUTICS AG (NASDAQ:NBRV) Recent Trading Information

NABRIVA THERAPEUTICS AG (NASDAQ:NBRV) closed its last trading session up +0.47 at 11.97 with 20,087 shares trading hands.